Pharmacokinetics and pharmacodynamics study of topiröxostat by oral administration in subjects with renal impairment

Japanese Pharmacology and Therapeutics

Volumn 43, Issue 5, 2015, Pages 639-645

  Nakazawa, Takashi ^a   Iwanaga, Takashi ^a   Ohashi, Tetsuo ^a   Saito, Kazuhiro ^a   Sakamoto, Ryusuke ^b   Okita, Misa ^c  

^a Fuji Yakuhin Co Ltd   (Japan)

^b SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^c Samoncho Clinic   (Japan)

Author keywords

FYX 051; Pharmacodynamics; Pharmacokinetics; Renal impairment subject; Topiroxostat

Indexed keywords

DRUG METABOLITE; N OXIDE; N1 GLUCURONIDE; N2 GLUCURONIDE; TOPIROXOSTAT; UNCLASSIFIED DRUG; URIC ACID;

ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; INULIN CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

EID: 84938079740     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Sato T, Ashizawa N, Matsumoto K, Iwanaga T, Nakamura H, Inoue T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxido-reductase inhibitor for the treatment of hyperuricemia. Bioorg Med Chem Lett 2009; 19 (21): 6225-9.
2. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 2004; 101 (21): 7931-6.
3. Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther 2011; 336 (1): 95-103.
4. Okamoto K, Kusano T, Nishino T. Chemical nature and reaction mechanisms of the molybdenum cofactor of xanthine oxidoreductase. Curr Pharm Des 2013; 19 (14): 2606-14.
5. Nakazawa T, Miyata K, Omura K, Iwanaga T, Nagata O. Metabolic profile of FYX-051 (4-(5-pyridin-4-y1-1H-[1,2,4] triazol-3-y1) pyridine-2-carbonitrile) in the rat, dog, monkey, and human: Identification of N-glucuronides and N-glucosides. Drug Metab Dispos 2006; 34 (11): 1880-6.
6. Omura K, Nakazawa T, Sato T, Iwanaga T, and Nagata O. Characterization of N-glucuronidafion of 4-(5-pyridin-4-y1-1H-[1,2,4]triazol-3-y1)pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug Metab Dispos 2007; 35 (12): 2143-8.
7. Shimo T, Ashizawa N, Moto M, Matsumoto K, Iwanaga T, Nagata O. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys. Toxicol Pathol 2009; 37 (4): 438-45.
8. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 2014; 18: 876-84.
9. Sugiyama A, Hashimoto H, Nakamura Y, Fujita T, Kumagai Y. QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol 2014; 54 (4): 446-52.